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Abstract
Background: In vitro reactions are useful to identify putative enzyme substrates, but in vivo
validation is required to identify actual enzyme substrates that have biological meaning. To
investigate in vivo effects of prolyl endopeptidase (PREP), a serine protease, on alpha melanocyte
stimulating hormone (α-MSH), we developed a new mass spectrometry based technique to
quantitate, in multiplex, the various forms of α-MSH.
Methods: Using Multiple Reaction Monitoring (MRM), we analyzed peptide transitions to quantify
three different forms of α-MSH. Transitions were first confirmed using standard peptides. Samples
were then analyzed by mass spectrometry using a triple quadrupole mass spectrometer, after
elution from a reverse phase C18 column by a gradient of acetonitrile.
Results: We first demonstrate in vitro that PREP digests biological active alpha melanocyte
stimulating hormone (α-MSH1–13), by cleaving the terminal amidated valine and releasing a
truncated alpha melanocyte stimulating hormone (α-MSH1–12) product – the 12 residues α-MSH
form. We then use the technique in vivo to analyze the MRM transitions of the three different forms
of α-MSH: the deacetylated α-MSH1–13, the acetylated α-MSH1–13 and the truncated form α-MSH1–
12. For this experiment, we used a mouse model (PREP-GT) in which the serine protease, prolyl
endopeptidase, is deficient due to a genetrap insertion. Here we report that the ratio between
acetylated α-MSH1–13 and α-MSH1–12 is significantly increased (P-value = 0.015, N = 6) in the
pituitaries of PREP-GT mice when compared to wild type littermates. In addition no significant
changes were revealed in the relative level of α-MSH1–13 versus the deacetylated α-MSH1–13. These
results combined with the demonstration that PREP digests α-MSH1–13 in vitro, strongly suggest thatα-MSH1–13 is an in vivo substrate of PREP.
Conclusion: The multiplex targeted quantitative peptidomics technique we present in this study
will be decidedly useful to monitor several neuropeptide enzymatic reactions in vivo under varying
conditions.
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In vitro reactions have been broadly applied to study the
characteristics of enzymatic reactions. However results
from in vitro experiments may not reflect true biologic
reactions. The enzymatic reactions revealed in vitro may
not even have the possibility of occurring in vivo because
of substrate availability due to of space, timing or other
restrictions. Therefore it is critical to validate enzymatic
reactions in vivo. Verifications to ensure co-localization of
the substrate and enzyme include immunohistochemistry
or in situ staining techniques, like X-Gal staining. Addi-
tionally, specific inhibitors have also been used to dem-
onstrate effect on enzyme activity, substrate or product
levels. However, specificity of the inhibitor is frequently
an issue. It has been difficult to demonstrate a direct effect
between a specific substrate and enzyme. Techniques
based on radioimmunoassay (RIA) are used to quantify
specific targets from a reaction but they often lack the spe-
cificity required to distinguish between various biologi-
cally important forms of the targeted molecules. Therefore
quantifying specific molecules has been a major hurdle to
decipher important biological reactions. Another impor-
tant issue is proper normalization when processing multi-
ple biological samples and in particular for signaling
neuropeptides with varying concentration. Reliable nor-
malization can be achieved by selecting of endogenous
controls from the targeted data set, using statistical treat-
ment [1]. In the case of enzymatic reactions, the optimal
normalization is to measure the ratio of enzyme substrate
to enzyme product.
In recent years, several studies have demonstrated the suit-
ability of mass spectrometry (MS) quantitative peptid-
omics, using stable isotope labels, particularly on
neuropeptides from mice hypothalamus and pituitary
(for review [2]). More recently, targeted quantitative pro-
teomics methods using triple quadrupole MS instru-
ments, allowed for quantitation without the use of stable
isotope labels [3]. This new method is highly sensitive
because the MS instrument is focused on specific targets,
instead of performing wide scans.
Neuropeptide hormones involve multiple maturation
steps, including cleavage by proteases, multiple post-
translational modifications and deactivation or degrada-
tion processes. Further, rapid perturbations of the neu-
ropeptide hormone concentration are a confounding
factor in quantitation analysis. Here, we propose a new
MS technique based on Multiple Reaction Monitoring
(MRM) transitions to quantitate in vivo the various forms
of the neuropeptide α-MSH, in a multiplex fashion.
Prohormone proopiomelanocortin (POMC) is the pre-
cursor of α-MSH, an important anorexigenic neuromodu-
lator and immunomodulator. α-MSH is mainly produced
in the pituitary and hypothalamus from the cleavage of
POMC by successive action of prohormone convertases 1
and 2 and carboxypeptidase E. α-MSH then goes through
several post-translational modifications to become ano-
rexigenically active. These post-translational modifica-
tions include C terminus amidation by α-amidating
monooxygenase and N terminus acetylation by an N-
acetyltransferase (for review [4]). The processing of
POMC in several endopeptides, occurs in the central nerv-
ous system, but also in peripheral organ such as skin,
where α-MSH is indeed involved in the stimulation of
melanocytes, but also in cutaneous stress responses [5].
There are multiple melanocortin receptors, involved in
several functions. α-MSH and derived peptides such as the
tripeptide KPV, are involved in anti-inflammatory mecha-
nisms through melanocortin receptors 4 (MC4R) and
possibly 1 (MC1R) [6] (for review [7]). α-MSH1–13 has
been shown to bind to hypothalamus melanocortin
receptors 3 and 4 (MC3R and MC4R) neurons and is also
associated to reduce food intake (for review [8]).
Mutations in the melanocortin pathway are the most
common known causes of mendelian forms of human
obesity [9]. Additionally, studies of mouse models have
identified candidate obesity genes that influence the
melanocortin pathway. Congenic mouse strains are iden-
tical to a background strain except for a defined chromo-
somal region from a donor strain. Obesity differences
between congenic and background are due to donor strain
alleles in the congenic region. Several studies have identi-
fied congenic mice in which the donor chromosomal
region contains genes that may influence levels of
melanocortin hormones, such as prohormone convertase
subtilisin/kexin-2 (Pcsk2) [10] and secretogranin V (Scg5)
[11]. However, assessment of the in vivo effects of these
genes on melanocortin pathways has been limited to
studies of one or a few peptide hormones at a time [11],
or has been limited in ability to study all forms of melano-
cortins by the availability of antibodies. Other studies
have shown effects of mutations in the melanocortin
pathway on responses to diet and exercise, but were una-
ble to determine specific changes in melanocortin hor-
mones due to lack of general assays to quantitate multiple
peptide hormones in individual samples [12].
The mouse model used in this study, PREP-GT, is deficient
in the serine protease, Prolyl endopeptidase (PREP, also
known as prolyl oligopeptidase – POP), due to a genetrap
insertion [13]. PREP is a post-proline cleaving enzyme
(for review [14]), which is expressed in a wide variety of
tissues, brain, lung, kidney, heart, muscle, uterus, spleen,
macrophages and others [15,16]. It has been shown to
digest in vitro α-MSH [17]. However, the product of the
enzymatic reaction was not characterized. PREP has also
many other putative substrates (for review [16]). SerumPage 2 of 9
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anorexia [18,19]. PREP has been associated with Alzhe-
imer's disease and neurodegeneration, implicating PREP
activity in memory [20]. No previous studies suggested
that PREP levels influence obesity. However, the mouse
model (PREP-GT), used in this study has shown a mater-
nal influence of PREP on the fat mass of adult progeny.
This mouse model has been phenotypically characterized
and it exhibits a parent of origin effects on obesity [13].
Here we measure three forms of α-MSH from mouse pitu-
itary: deacetylated α-MSH1–13, acetylated α-MSH1–13 andα-MSH1–12, a truncated form which results from the activ-
ity of serine proteases, in PREP-GT mice and demonstrate
a highly sensitive and specific method to quantitate neu-
ropeptides in vivo.
Results
α-MSH1–12 is the product of PREP activity on the substrate α-MSH1–13
We first tested the ability of multiplex, targeted, quantita-
tive peptidomics by analyzing the in vitro reaction of PREP
on α-MSH1–13. We identified 5 and 7 MRM transitions
using standard α-MSH1–13 and α-MSH1–12, respectively.
Then these MRM transitions were targeted on a time
course experiment, in which we exposed α-MSH1–13 to
recombinant PREP (rPREP). We observed a very good
concordance of the α-MSH1–12 quantitation for each tran-
The seven α-MSH1–12 MRM transitions (MRMT_1 to MRMT_7) used are increasing in a synchronous fashion during the time courFigure 1
The seven α-MSH1–12 MRM transitions (MRMT_1 to MRMT_7) used are increasing in a synchronous fashion 
during the time course. Peak areas of each MRM transition are shown for each time point on a log scale.Page 3 of 9
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four time points. The increase in the quantity of α-MSH1–
12 over time demonstrates that the enzymatic activity of
rPREP on α-MSH1–13produced α-MSH1–12 [see Additional
File 1]. α-MSH1–12 is the product rPREP activity, we used
it to normalize the quantitative results obtained in the five
MRM transitions of α-MSH1–13. Using this method, we
were able to confirm the relative amount of α-MSH1–13
decreases over time in the reaction mixes (Fig. 2) This
experiment demonstrated that α-MSH1–13 is an in vitro
substrate of rPREP and the product of the enzymatic reac-
tion is α-MSH1–12. It also confirmed the suitability of the
MRM transitions we identified to quantitate both α-
MSH1–13 and α-MSH1–12 in multiplex.
PREP-GT pituitary multiplex quantitative analysis of three 
forms of α-MSH
We developped an MS method with 4, 5 and 7 MRM tran-
sitions, respectively, to quantitate in vivo the deacetylated
α-MSH1–13, the anorexigenically active acetylated α-
MSH1–13 and the truncated form, α-MSH1–12, which
results from the activity of PREP [see Additional File 2].
The pituitary PREP level in the PREP-GT mice were
checked by western blotting and these mice are clearly
deficient in PREP enzyme in the homozygote mice (Fig.
3).
In this experiment, the three forms of α-MSH were meas-
ured in pituitaries of littermates generated from parents
heterozygous for the PREP-GT knockout (PREP+/gt). The
levels of deacetylated α MSH1–13 and acetylated α MSH1–
13 were not significantly different between the three classes
of littermates [homozygous PREP-GT (PREPgt/gt), hetero-
zygous (PREP+/gt), and homozygous wild type (PREP+/+)].
However, there was a statistically significant increase in α-
MSH1–13, level relative to α-MSH1–12 level, in PREPgt/gt
mice (Fig. 4). The fold change of acetylated α-MSH1–13 vs
acetylated α-MSH1–12, between the PREPgt/gt mice and the
In vitro time course of PREP activity on α-MSH1–13Figure 2
In vitro time course of PREP activity on α-MSH1–13. The increase of α-MSH1–12 (pink line) fits a linear regression with R2 
= 0.9370 (black line). The ratio of α-MSH1–13/α-MSH1–12 decreases in a corresponding fashion (blue line).Page 4 of 9
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p-value of 0.015 (N = 6).
Discussion
We demonstrated a label free multiplex quantitative pep-
tidomics method that allows the targeting of multiple
peptides and their isoforms. A key feature is the multiplex
ability that allows the comparison of several peptide tar-
gets in a single sample. This is very advantageous when
monitoring an enzyme substrate and its product and
therefore allows targeting of specific enzymatic activities.
This method differs from current quantitative MS tech-
niques using isotopically labeled tags. Typically in these
techniques, an isotopically labeled tag is attached to the
peptides in one sample and then mixed with another sam-
ple, which were labeled with a chemically identical tag
that differs in mass, generally due to different numbers of
heavy isotopes of carbon, hydrogen or nitrogen. Because
the tags are chemically identical but differ in mass, one
can compare the intensity of the labeled peptide pairs to
determine relative abundances of the peptides in the sam-
ple. This is a great technique for discovery of differential
peptides. However it is limited by the characteristics of the
labeling which can introduce a label bias. Indeed, an iso-
topic label needs a site to attach itself on the target mole-
cules, which creates a bias for some peptides. For example,
TMAB label, along with many other tags, requires a free
amine [2] and thus would not be able to attach itself to α-
MSH1–12, since its N-terminus is acetylated. It is also not
clear if TMAB or similar labeling could be used to quanti-
tate deacetylated, amidated α-MSH1–13 versus acetylated,
amidated α-MSH1–13. This is a problem for relative com-
parison of distinct peptides within a sample. Nevertheless,
the label quantitative technique works well to compare
each peptides paired from different samples. This makes
the multiplex peptides quantitation technique described
here an ideal follow up technique on discovery made by
isotopic label experiment. Multiple forms of the discov-
ered peptides and their associated biology can be investi-
gated using MRM transitions, without the label method
restriction and bias.
Another key advantage of this MRM technique is the
increase in sensitivity and selectivity, allowing much
lower detection limits, than typical MS survey experi-
ments. This helps greatly for the detection of lower abun-
dance neuropeptides. Combined with the increased
dynamic range of MS instruments, the coverage of a wide
concentration range is possible.
The quantitative technique used in this study can target
theoretically most peptides, provided that the MRM tran-
sitions encountered in biological samples are identified
and the MS instrument is tuned to quantitate them. The
use of a standard improves the tuning process greatly,
which is important to ensure adequate detection limits.
This makes the technique very suitable for quantitative
neuropeptidomics, with a special emphasis on monitor-
ing multiple forms of target peptides and/or enzymatic
reactions. Compared to RIA, the technique is not
restricted by the availability of good antibodies, which
can be challenging for protein of low specificity. The tech-
nique is also very suitable for analyzing molecules with
only small differences, such as PTMs. Because of its sensi-
tivity and specificity, we see our multiplex quantitative
peptidomics technique as a potent improvement over
existing techniques for neuropeptide studies, such as dis-
ease states, inhibitor studies, and others.
Our in vitro experiment confirmed PREP digests α-MSH1–
13 and the appearance of α-MSH1–12 in the reaction mix
revealed that α-MSH1–12 is the product of PREP on α-
MSH1–13. The reduced level of α-MSH1–12 in vivo in a PREP
deficient pituitaries confirms that the production of α-
MSH1–12 in vitro is due to PREP itself and not some con-
tamination form other enzymes in the rPREP source.
Reciprocally, our in vitro data strongly suggest that the
reduced level of α-MSH1–12 in PREP-GT pituitaries is due
to reduced PREP levels.
α-MSH1–12 has different biological activity than α-MSH1–
13 because α-MSH1–12 does not stimulate action potentials
in MC4R expressing neurons. (Wallingford et al. unpub-
lished data). However, it is possible or even probable that
α-MSH1–12 may activate other receptors that would not be
the target of the C-terminus of α-MSH1–13. Since it has
been shown that the tripeptide KPV, corresponding to the
three C-terminus of α-MSH1–13, has anti-inflammatory
Western blots of pituitary from PREP-GT littermate mice with PREP antibody: From left to right Wild Type (WT), PREP-GT heter zygotes (HT) and PREP-GT ho ozygotes (GT)Figure 3
Western blots of pituitary from PREP-GT littermate 
mice with PREP antibody: From left to right Wild 
Type (WT), PREP-GT heterozygotes (HT) and 
PREP-GT homozygotes (GT). The loading is shown 
below from a Ponceau S stained gel.Page 5 of 9
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MSH1–12, lacking a C-terminus valine, can't act as ligand
to MC1R. In addition, the cleavage of the terminal valine
results in the loss of α-MSH C-terminus amide, which
may also affect α-MSH ability to act as a ligand on some
melanocortin receptors.
While not significant when comparing the heterozygote to
the wild type pituitaries, the ratio of acetylated α-MSH1–13
and α-MSH1–12 appears correlated to PREP levels. This
suggests an additive effect of PREP on the digestion of α-
MSH by PREP.
In this experiment, we did not verify the absolute quantity
of α-MSH1–13 by itself but we hypothesize that in a
reduced PREP level condition, α-MSH1–13 may have a
longer life as its turnover is slowed. We did not observe a
significant change in the N-acetyltransferase activity (from
an unknown enzyme), which is consistent with a stable
absolute level of α-MSH. Our results support previous
reports of deacetylated α-MSH1–13 in the pituitary [22].
Further leptin, which has been reported to regulate the N-
acetyltransferase activity of α-MSH1–13 [23], was not
found significantly correlated with PREP-GT mice pheno-
type [13]. This is in support of previously published evi-
dences that pituitary have a sensing mechanism of
acetylated α-MSH1–13 concentration and they release α-
MSH1–13 accordingly [24], suggesting a feedback inhibi-
tion mechanism that could result in an unchanged abso-
lute quantity of acetylated α-MSH1–13 in the PREP-GT
mouse. This is in agreement with the lack of obesity phe-
notype in the analyzed cross [13].
ratio of acetylated α-MSH1–13 acetylated over deacetylated α-MSH1–13 and acetylated α-MSH1–13 over α-MSH1–12 in three gen-otypes of littermate mice from PREP-GT mous  strainFigure 4
ratio of acetylated α-MSH1–13 acetylated over deacetylated α-MSH1–13 and acetylated α-MSH1–13 over α-MSH1–
12 in three genotypes of littermate mice from PREP-GT mouse strain. Left: acetylated α-MSH1–13/deacetylated α-
MSH1–13; Right: α-MSH1–13/α-MSH1–12.Page 6 of 9
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rapidly changing levels. To assess enzymatic activity on
neuropeptides across biological replicates, it is critical to
normalize the quantity with endogenous controls. The
most suitable endogenous control for enzymatic activity
on a substrate is indeed the product of the enzymatic reac-
tion.
Conclusion
We have established that PREP digests α-MSH1–13 and
produce α-MSH1–12 in vitro. The reduced relative level ofα-MSH1–12 in a reduced PREP level background strongly
suggests that α-MSH1–13 is a substrate of PREP in vivo.
The multiplex targeted quantitative peptidomics tech-
niques demonstrated in this study are a powerful new tool
for quantitation of neuropeptides. It opens the possibility
for experiments with higher specificity and sensitivity that
allows in vivo multiplex monitoring of several neuropep-
tides, under varying conditions.
Methods
Identification of MRM transitions using standards
C-amidated α-MSH1–13 (deacetylated α-MSH; American
Peptide cat# 56-0-24), N-acetylated, C-amidated α-MSH1–
13 (Bachem cat# H-1075) and N-acetylated α-MSH1–12,
(custom peptide synthesis from Genscript Corporation;
sequence: acetyl-SYSMEHFRWGKP) were directly infused
into a Thermo Scientific TSQ Vantage triple quadrupole
mass spectrometer to identify the optimum MRM transi-
tions generated by these three compounds. We restricted
the analysis to the prevalent charge state of each peptide.
MRM transitions were then validated by spiking the three
compounds in a biological sample and then analyzed as
described in paragraph B below (PREP in vitro reaction).
PREP in vitro reaction
We used recombinant 81 Kd PREP (denoted rPREP) from
R&D systems (Cat# 4308-SE), and N-acetylated, C-ami-
dated α-MSH1–13 (Bachem cat# H-1075). 2 μg α-MSH1–13
was incubated in the presence of 50 ng rPREP in a final
volume of 50 μL assay buffer (25 nM Tris, 0.25 M NaCl,
pH 7.5) for 0, 15, 30 and 60 min at 25°C. Reaction was
terminated, by lowering pH to 3.5 by adding HCl 0.7 M.
Samples were then desalted using C18 ziptip (Omix C18)
following manufacturer instructions.
10 μL of the reaction mixes were analyzed by mass spec-
trometry using a Thermo Scientific TSQ Vantage with a
Michrom Bioresources MDLC and a CTC Pal Autosam-
pler. Peptides were separated using a reverse phase
Michrom Magic C18 (200 umx150 mm) column at a flow
rate of 2 μL per min. and a 90 min gradient of 2% B to
60% B over 60 minutes (A = 0.1% Formic Acid, B = 100%
acetonitrile). Scan width was set at 0.002. Q1 and Q3 peak
widths at 0.7.
Peak areas for several MRM transitions for each target pep-
tides were then calculated using the software Xcalibur ver-
sion 2.0.7. The MS method was targeting, respectively, 5
and 7 MRM transitions for α-MSH1–13 and α-MSH1–12
Generation of PREP-GT mice
PREP-GT is a Genetrap mouse generated from the BayGe-
nomics clone RRM213 and back crossed to B6. PREP gen-
etrap presence is confirmed at every generation by
genotyping three microsatellite markers (D10Mit148 and
D10Mit55 and D10Mit36).
Mouse maintenance, diet and dissection
An F2 colony was created by breeding PREPgt/wt littermates
to produce pups that were heterozygous PREPgt/wt (HT),
gene-trap PREPgt/gt(GT), or wild-type PREPwt/wt (WT).
Breeding pairs were maintained in a 14 h light/10 h dark
cycle, 21 ± 2 (SD) °C temperature, 25% or greater humid-
ity and fed a breeder chow (LabDiet® 5015, PMI Nutrition
International, St. Louis, MO). Pups were weaned at 3
weeks of age and separated by gender. They were housed
3–5 mice in shoebox cages and placed ad libitum low fat
AIN-76A diet (Research Diets, Inc., New Brunswick, NJ)
with deionized water. Mice were sacrificed at 120 ± 3 (SD)
days of age, after ~15 hours. The pituitaries were dissected
and flash frozen.
Pituitary Western blots
Protein was extracted from whole pituitary samples of
each genotype. The pituitary was homogenized on ice in
100 μL NP-40 lysis buffer (150 mM NaCl, 1.0%, NP-40
Tergitol, 50 mM Tris, pH 8.0) supplemented with protease
inhibitor cocktail (Roche Cat# 1 697 498 001). The sam-
ples were centrifuged at 4°C for ten minutes at 14,000 g.
The supernatant was retained and used for Western Blot
analysis. Protein concentration was determined through
micro-BCA assay (Cat # 23235 Thermo Scientific) and 2.5
μg of total Protein was run on NuPAGE 4–12%Bis-Tris
Gel and transferred to GE Nitrocellulose membrane. We
performed Ponceau S staining on unblocked membrane
for loading control and blocked with 5% milk overnight
in a cold room. The membrane was blocked with Primary
Antibody (Abcam ab58988) for one hour, washed three
times with TBST for ten minutes, then blocked with sec-
ondary antibody (Abcam ab6721) for one hour, and
finally washed another three times for ten minutes with
TBST.
Mice pituitary multiplex quantitative analysis of 3 forms of 
α-MSH
The pituitary sample preparation is adapted from meth-
ods previously published [25]. Dissected pituitaries werePage 7 of 9
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times for 5 s and incubated at 70°C for 20 min. A 100 μL
of 0.2 M phosphate buffer, pH 9.5 was added, and the
homogenate was centrifuged at 50,000 g for 40 min at
4°C. The pellet was re-suspended in 200 μl of 0.2 M phos-
phate buffer, pH 9.5, and centrifuged at 50,000 g for 40
min at 4°C. Supernatant were combined and diluted with
200 μL of 0.4 M phosphate buffer, pH 9.5. The pH was
then adjusted to 9.5 with 1 M NaOH. The samples were
then run through Strata-X columns per manufacturer
instruction (Phenomenex: Strata C18-E (55 um, 70A) 200
mg/3 mL; Cat# 8B-S001-FBJ). After elution with 60% ace-
tonitrile, samples were lyophilized, resuspended in 100
μL 2% acetonitrile, 0.1% formic acid and sonicated in
ultra sonic bath for 10 minutes.
Aliquotes containing 2 μg were analyzed with the same
equipment and conditions than described above for the in
vitro reactions mixes, except that we injected 20 μL of the
samples and the MS method was targeting, respectively, 4,
5 and 7, MRM transitions for the prevalent charge state of
the deacetylated α-MSH1–13, the acetylated α-MSH1–13
and α-MSH1–12.
Statistical analysis
Statistical significance of quantitation across genotypes
was calculated by one tail Student t-test using Microsoft
Excel.
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